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Part I: Introduction
Since 1984, the Food and Drug Administration (FDA) has approved over 8,000 generic
drugs, which comprise approximately seventy-eight percent of currently filled prescriptions.1
The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) has
governed the approval of generic drugs.2 The Act provides an expedited approval process for
generic drugs that have an identical Reference Listed Drug (RLD). Provided a generic drug is
the “same” as its listed drug counterpart, its manufacturer is permitted to forgo clinical testing,
on the condition that the drug maintains the same label as the listed drug.3 The generic drug
manufacturers have no authority to modify or update their own safety labels.4 The inability to
independently update labels has led to issues concerning generic drug manufacturers’ liability for

Fact Sheet: New User Fees for Generic Drugs Will Enhance American’s Access to Less Expensive Drugs and
Generate Major Cost Savings, http://www.fda.gov/RegulatoryInformation/Legislation/
FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm310992.htm (last
visited Nov. 5,2014).
2
See 21 U.S.C. 355(j) (1)-(2). See also, Drug Price Competition and Patent Term Restoration Act of 1984 (HatchWaxman Amendments) Before the S. Comm. on the Judiciary, (2003) (statement of Daniel E. Troy, Chief Counsel,
U.S. Food and Drug Administration).
3
Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Leveling Before the Energy and
Commerce Subcomm. On Health, U.S. H.R., (2014) (statement of Ralph. G. Neas, President and CEO, The Generic
Pharmaceutical Association).
4
Id.
1

2

failure to warn of safety concerns, which have been recently addressed by the U.S. Supreme
Court.5
Congress has begun to address these concerns with the enactment of the Generic Drug
User Fee Amendments of 2012 (“GDUFA”).6 The GDUFA recognizes the growth of the generic
drug industry by expediting the approval process for generics, saving time and money for the
industry, and ensuring Americans have access to low cost, quality medicine. In exchange for
faster approval times, the generic industry must pay user fees, as the branded pharmaceuticals
do.7 The GDUFA is the beginning of major reform for the generic drug industry, placing some
of the same obligations and benefits on the generic industry that the brand name manufacturers
have.
The growth of the generic industry and the issues presented in recent Supreme Court
cases have prompted the FDA to reconsider current federal mandate and to suggest generic drug
manufacturers be permitted to update their safety labels in response to safety issues that have
been discovered.8 The proposed regulation would require generic-drug makers to update their
labels in light of newly acquired safety information to avoid injury to consumers, which could
result in legal liability.9 This Note argues that allowing generic-drug makers to update safety
labels as soon as new information is received will increase patient safety and prevent injuries by

5

Jennifer M. Thomas, FDA Proposes a Rule that Would Undercut Generic Drug Preemption, FDA L. BLOG
(September 2, 2014), http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2013/11/fda-proposes-a-rule-thatwould-undercut-generic-preemption.html
6
Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-144, §908, 126 Stat. 993 (2012).
7
Fact Sheet, supra note 1.
8
Joe Carlson, FDA’s Generic-Drug Label Rule Draws Controversy, MODERN HEALTHCARE (September 2, 2014),
http://www.modernhealthcare.com/article/20140628/MAGAZINE/306289979.
9
Id.
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providing timely updates to safety information.10 This would also allow generic drugs that no
longer have a brand-name counterpart to update their labels.11
These changes may also have an impact on manufacturer’s exposure to failure-to-warn
liability. Under the Supreme Court’s 2011 ruling in PLIVA v. Mensing, generic drug makers are
unable to add new side effect and safety information to product labeling and therefore should not
be held accountable for any failure-to-warn claims.12 Currently, access to the courts depends on
whether an individual has been prescribed a brand-name or generic drug.13 Many fear that if the
proposed regulatory change is approved, it may allow consumers to file failure-to-warn claims
against generic drug manufacturers.14 Once generic drug makers have the right to change their
label, they are responsible for knowing the full effects of the drugs they produce, and may be
sued for failing to timely update their labels.15 The FDA notice of the proposed rule
acknowledges the proposed regulation may also change generic drug manufacturer’s liability. 16
Although the proposed regulations may have a significant impact on generic drug makers’
liability, such discussion is beyond the scope of this note.
Part II of this Note will introduce background legislation and regulations concerning the
labeling of brand-name and generic drugs. It will describe the subsequent amendments to food

10

Id.
Id.
12
PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011); Silverman, Ed. How Fast Should a Generic Drug Maker
Update Labeling with New Safety Info? THE W.S.J. PHARMALOT, (Sept. 3, 2014),
http://blogs.wsj.com/pharmalot/2014/09/03/how-fast-should-a-generic-drug-maker-update-labeling-with-newsafety-info/; See also Mutual Pharm. Co. v. Bartlett, 133 S. Ct. 2466 (2013).
13
Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Labeling Before S. Comm. On
Health, Comm. On Energy and Commerce, U.S. H.R., (2014) (statement of Janet Woodcock, Director, Center for
Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Service).
14
Id.
15
Carlson, supra note 8.
16
Freidman, Ezra and Abraham L. Wickelgren. Who (if Anyone) Should be Liable for Injuries from Generic Drugs?
(citing 67986 Federal Register, Vol 78, No. 219, November 13, 2013.
11
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and drug legislation in response to the growth of generic drugs over the past few decades. Part II
will also introduce the 2013 proposed regulatory amendments which would provide generic
manufacturers the ability to independently update safety labels. Part III of this Note will discuss
the benefits of independent label changes to public policy and patient safety while keeping costs
significantly lower than brand-name counterparts.
Part II: Background/Overview
A. Statutory Background
The Federal Food, Drug, and Cosmetic Act (“FD&C Act”) and the Public Health Service
Act (“PHS Act”) “provide [the] FDA with authority over the labeling for drugs and biological
products.”17 The Acts also authorizes the FDA to enact regulations to facilitate the review and
approval of applications regarding the labeling for those products.”18 Section 502(f) of the
FD&C Act states that “a product is misbranded unless its labeling bears adequate directions for
use, including adequate warnings against, among other things, unsafe dosage, methods, duration
of administration, or application.”19 Section 502(j) of the Act mandates that “a product is
misbranded if it is dangerous to health when used in the manner prescribed, recommended, or
suggested in its labeling.”20 These statutes created new standards for drug manufacturer’s
products and facilities.
In 1984, the FD&C Act was amended to include the Drug Competition and Patent Term
Restoration Act, more commonly known as The Hatch-Waxman Act.21 The Hatch-Waxman Act

17

See 21 U.S.C. 301. See also 42 U.S.C. 201.
Woodcock, supra note 13.
19
Id.
20
Id.
21
Wolfman, Brian & Anne King, Mutual Pharmaceutical Co. v. Bartlett and Its Implications, U.S.L.W. (Sept. 19,
2014), available at http://scholarship.law.georgetown.edu/facpub/1297.
18
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provided a less stringent approval process for generic drug makers. The generic manufacturer is
now required to submit an abbreviated new drug application, showing the generic drug is the
“same” as a previously approved brand-name drug, and the generic is “bioequivalent” to the
brand name drug.22 Under the “sameness” requirement, the generic manufacturer must show that
the generic drug provides the same safety and efficacy, by proving that the generic drug has the
same active ingredient, is identical in strength, dosage and administration, and has the same
safety label.23 The Act exempted generic manufacturers from the “expensive, time-consuming,
and ultimately repetitive clinical testing and trials that already had been performed on the
innovator drug.”24 In the twenty-two years preceding the Act, only fifteen generics had been
approved by the FDA. One year after the Act, more than 1,000 drugs approvals were submitted
to the FDA. The Act has resulted in billions of dollars of savings to the health care industry and
consumers.25
Currently, for most substantive changes to drug labeling, a brand-name manufacturer
must submit an approval supplement and obtain FDA approval for the change.26 FDA
regulations also require manufacturers of pharmaceutical and biological products to submit
reports of adverse drug experiences that occur after approval.27 In promotion of public health,
the FDCA permits certain labeling changes based on newly acquired safety information about
the drug when the manufacturer submits a “changes being effected” (“CBE-0”) supplement

22

Id.
Neas, supra note 4.
24
Id.
25
Id.
26
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, 78 Fed.
Reg. 67985 (proposed Nov. 13, 2013), available at https://www.federalregister.gov/articles/2013/11/13/201326799/supplemental-applications-proposing-labeling-changes-for-approved-drugs-and-biological-products
27
Id.
23
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describing the change.28 Newly acquired safety information is defined by the FDCA as
"information derived from a clinical trial, an adverse event report, a post approval study . . . peer
reviewed biomedical literature, data derived from the post-market risk identification and analysis
system under section 505(k); or other scientific data deemed appropriate by [the FDA]."29 When
this information is received, the brand drug must update their warnings labels to reflect the new
information.
The CBE-0 supplement regulations “allow application holders to comply with the
requirement to update labeling promptly to include a warning about a clinically significant
hazard as soon as there is reasonable evidence of a causal association with a drug . . . .”30
According to the 2008 amended regulations governing the CBE-0 process, a CBE-0 labeling
supplement is appropriate only to show new information. The 2008 amendments clarified that
the supplement may be used to “add or strengthen a contraindication, warning, precaution, or
adverse reaction only if there is sufficient evidence of a causal association with the approved
product.”31 The FDA reviews all labeling changes proposed in a CBE-0 supplement and the
underlying data and research supporting the change. The FDA then accepts, rejects, or requests
modifications to the proposed changes as deemed appropriate, and can bring enforcement action
if the information makes the product’s label false or misleading.32 Also, if the newly acquired
information causes the product to no longer meet FDA standards, the agency can take action by
rescinding the drug’s approval.33

28

Id., See also 21 C.F.R. §§ 314.70(c) (6) (iii) and 601.12(f) (1).
See 21 U.S.C. 505(o)(2)(C)
30
See 78 Fed. Reg. 67985, see also 21 C.F.R. 201.57(c).
31
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, 78 Fed.
Reg. 67985-02 (proposed Nov. 13, 2013) (to be codified at 21 C.F.R. pt. 314 and 601).
32
See 21 U.S.C. 352(a).
33
See 21 U.S.C. 355(e), 355-1.
29
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B. The 2012 Enactment of FDASIA/GDUFA: Paving the way for Generic Label Updating?
In 2010, seventy-eight percent of pharmaceutical prescriptions were filled with generic
brands.34 Today, the top ten drugs filled in America are all generic brands.35 Over the past
decade, generic drugs have provided a savings of over $824 billion dollars to the nation’s health
care system in the last decade.36 In response to the rapid growth of generic drugs over the past
decades, Congress, in 2012, enacted the Generic Drug User Fee Act (“GDUFA”) as a part of the
Food and Drugs Administration Safety and Innovation Act (“FDASIA”).37 GDUFA allows for
more speed in approving generic drugs while ensuring safety and low costs by requiring generic
manufacturers to pay fees to supplement the costs of reviewing generic drug applications and
inspecting facilities.38 As the FDA has explained “Recognizing the critical role generic drugs
play in providing more affordable, therapeutically equivalent medicine, the Generic Drug User
Fee program is designed to keep individual fee amounts as low as possible to supplement
appropriated funding to ensure that consumers continue to receive the significant benefits offered
by generic drugs…”39
The FDASIA gives the FDA the authority to collect user fees from the pharmaceutical
industry to “fund reviews of innovator drugs, medical devices, generic drugs and biosimiliar

34

Gary Gatyas, IMS Institute Reports U.S. Spending on Medicines Grew 2.3 Percent in 2010, to $307.4 Billion, IMS
HEALTH (April 19, 2011), http://www.imshealth.com/vgn-ext-templating/
v/index.jsp?vgnextoid=1648679328d6f210VgnVCM100000ed152ca2RCRD.
35
von Koeckritz, Karen. Generic Drug Trends- What’s Next? (April 11, 2012), http://www.pharmacytimes.com
/publications/issue/2012/April2012/Generic-Drug-Trends-Whats-Next.
36
Generic Drug User Fee Act Program Performance Goals and Procedures, (Nov. 10, 2014), available at
http://www.fda.gov/downloads/ForIndustry/UserFees/GenericDrugUserFees/UCM282505.pdf
37
Fact Sheet, supra note 1.
38
Generic Drug User Fee Amendments of 2012. U.S. Food and Drug Administration, (Nov. 10, 2014), available at
http://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/default.htm. See 112 H.R. 3988, 2012 H.R.
3988,112 H.R. 3988.
39
Supra note 35.
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biological products.”40 The FDASIA also encourages innovation by providing a “breakthrough
therapy” designation for certain drugs that may be substantially superior to current drugs on the
market. This designation would allow for an expedited review and approval process through the
collection of fees to create additional resources.41 The FDASIA was also implemented to protect
the drug supply chain and to ensure patients have access to drugs they need by extending the
FDA’s detention authority and increasing penalties for adulterated and counterfeit drugs. 42
The purpose of the GDUFA is to increase safety by requiring that any manufacturer who
participates in the U.S. generic drug industry be inspected biennially.43 It also will “deliver
greater predictability and timeliness to the review of generic drug applications, slashing review
times and saving industry time and money.”44 The GDUFA also requires that any domestic or
international facility involved in the manufacture of generic drugs and their ingredients be
identified upon their sale in the United States to increase transparency in the complex, global
pharmaceutical market.45 All facilities and companies selling generic drugs must register
annually with the FDA.46 This includes manufacturers of active pharmaceutical ingredients
whose products may be used in US products through another manufacturer or facility that
repackages generic drugs.47 The FDA has laid out guidance on which companies need to selfidentify and what information they are required to provide to the FDA.48 In its guidance

40

Food and Drug Administration Safety and Innovation Act (FDASIA), (Jan. 1, 2015), available at
http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmen
dmentstotheFDCAct/FDASIA/
41
Id.
42
Id.
43
Supra note 35.
44
Fact Sheet, supra note 1.
45
Id.
46
112 H.R. 3988. See also Gaffney, Alexander. FDA Releases Guidance on Facility Registrations, Payments under
GDUFA, (Jan. 21, 2015), http://www.raps.org/regulatoryDetail.aspx?id=7435.
47
Id.
48
Id.
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documents, the FDA explained that “[t]he information provided through self-identification will
enable quick, accurate and reliable surveillance of generic drugs and facilitate inspections and
compliance.”49
The GDUFA also aims to cut down the review time of generic drug applications from
thirty-one months to about ten months. The funds collected from the user fees, which is stated to
be one half of one percent of generic drug sales, will be used to assess the safety of generic
drugs.50
The user fees result in benefits to the public health by financing the FDA to carry out
functions that it could not do previously. By cutting the review time of a generic drug
applications, the GDUFA will increase savings in development time, while decreasing the costs
of bringing a generic drug to the market.51 Therefore, this may also result in a decline in costs to
consumers.52
C. Recent Supreme Court Cases
Recent Supreme Court cases have addressed the issue of whether generic drug
manufacturers should be liable for failing to provide adequate warnings on drug labels.53 This
wave of lawsuits began with Wyeth v. Levine in 2009. 54

49

Id.
Sullivan, Thomas. The Food and Drug Administration Safety and Innovation Act (FDASIA): Summary of
GDUFA, MDUFA, BsUFA and Pediatrics, POLICY AND MEDICINE (NOV. 10, 2014),
http://www.policymed.com/2012/07/the-food-and-drug-administration-safety-and-innovation-act-fdasia-summaryof-gdufa-mdufa-bsufa.html
51
Supra note 26.
52
Id.
53
Woodcock, supra note 13.
54
Wyeth v. Levine, 555 U.S. 555 (2009)
50

10

In Wyeth, the patient was injured by using a brand-name anti-nausea drug through an IVpush method. The patient claimed the drug’s label was defective because it failed to instruct
clinicians to use an IV-drip method, rather than the higher-risk push method.55 The patient filed
a failure-to-warn suit in state court against the drug manufacturer, Wyeth for failing to update the
product’s label with newly acquired safety information, even though the labels conformed to
FDA regulations.56
The Supreme Court determined that federal law does not preempt a state law failure to
warn claim for brand name drugs.57 The Court explained that “[i]t has remained a central
premise of federal drug regulation that the manufacturer bears responsibility for the contents of
its label at all times.”58 The court held that the manufacturer must create an adequate safety label
and ensure it is up to date as long as the product is being sold.59 The Court opined “Wyeth failed
to demonstrate that it was impossible for it to comply with both federal and state requirements . .
. the mere fact that the FDA approved . . . [the] label does not establish that it would have
prohibited such a change.”60 The Court held that Wyeth could have strengthened the warning
labels under the FDA’s CBE-0 regulation to comply with state law.61 The Court’s holding in
Wyeth sent a clear message to brand-name drug manufacturers that: “if they do not unilaterally

55

See Wyeth, 555 U.S. 555. See also Boyd, Marie. Unequal Protection Under the Law: Why FDA Should Use
Negotiated Rulemaking to Reform the Regulation of Generic Drugs, 35 Cardozo L. Rev. 1525, 1530 (2014).
56
Goldstein, Jacob. Wyeth v. Levine: The Mother of All Preemption Cases, W.S.J. BLOGS (Nov. 9, 2014),
http://blogs.wsj.com/health/2008/09/19/wyeth-v-levine-the-mother-of-all-preemption-cases/
57
Supra note 13.
58
Wyeth, 555 U.S. at 570-71.
59
Id.
60
Wyeth, 555 U.S. at 573.
61
Boyd, supra note 55.
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strengthen their labels when they know it is necessary, they will face liability in the state court
system.”62
In 2011, the Supreme Court distinguished Wyeth in the subsequent case PLIVA v.
Mensing.63 In PLIVA, the patients alleged they developed tardive dyskinesia after using the
generic drug metoclopramide. The patients claimed the generic drug label did not contain
adequate warnings of this adverse side effect.64 The manufacturer of the drug argued that: “(1)
FDA regulations require the warnings on generic pharmaceuticals to be the same as those of the
brand-name product; and (2) they had no ability to unilaterally add or strengthen warnings
without FDA approval.”65 The Court agreed with the manufacturer, and held the claim was
preempted because generic manufacturers cannot add further warnings without violating FDA
regulations under the Hatch-Waxman Act.66
The holdings in Wyeth and PLIVA suggest that “The Supreme Court has determined that
generic manufacturer’s lack of independence with respect to drug safety labeling makes it
impossible for them to comply with both Federal drug labeling requirements, and state tort law
(failure-to-warn or design-defect) requirements.”67 The holdings in Wyeth and PLIVA suggest
that access to the courts depends on whether a consumer purchased a generic or a brand-name
drug.68

62

Sarah S. James, Note, Generic Drug Manufacturer Liability: Achieving a Balance Between Consumer
Affordability and Safety, 38 Iowa J. Corp. L. 177, 182 (2013).
63
See PLIVA, 131 S. Ct. 2567.
64
Id.; Rose, Beth S., Charles J. Falletta & Vincent R. Lodato. Pliva, Inc. v. Mensing–United States Supreme Court
Holds That Failure To Warn Claims Against Generic Pharmaceutical Manufacturers Are Pre-Empted By Federal
Law, N.L.R. (Nov. 10, 2014), http://www.natlawreview.com/article/pliva-inc-v-mensing-united-states-supremecourt-holds-failure-to-warn-claims-against-generic
65
Id.
66
Id.
67
Thomas, supra note 4.
68
Supra note 13.
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In 2013, the Supreme Court decided Mutual Pharmaceutical Co. v. Bartlett.69 In Bartlett,
the plaintiff suffered an adverse effect from taking the generic medication Sundilac.70 The
patient, who took the prescribed medication to alleviate muscle pain, developed Stevens Johnson syndrome and toxic epidermal necrolysis and became extremely disfigured as a result.71
This side effect was originally listed as “a possible adverse reaction” on the safety label and was
later moved to the “warnings” section of the generic label in conformance with the FDA’s
recommendation.72
The Supreme Court held in Bartlett that federal law preempts a state-law design-defect
claim against a generic drug manufacturer under PLIVA.73 The Court first decided that New
Hampshire does not have a “pure” design-defect cause of action, which would require a jury to
balance the risks and benefits of an FDA approved drug to determine if it is “unreasonably
dangerous”.74 As the FDA argued in its brief, this would undermine their assurance of approved
drugs on a state-by-state and case-by-case basis, as well as Congress’s purpose that FDA
approvals are made by experts applying science based judgment.75 The Supreme Court
determined that New Hampshire’s design defect cause of action includes an evaluation of the
adequacy of the label.76 Through the design-defect analysis, the Court determined that generic
drug manufacturers should not be held accountable for failure-to-warn or design-defect claims

69

See Bartlett, 133 S. Ct. 2466.
Id.
71
Id.
72
Wolfman, supra note 18.
73
Bartlett, 133 S. Ct. 2466; Wolfman, supra note 18.
74
Bartlett, 133 S. Ct. at 2470.
75
Id.; Brief for the United States as Amicus Curiae, p. 25, Mutual Pharm. Co. v. Bartlett, 133 S. Ct. 2466 (2013).
76
See Bartlett, 133 S. Ct. 2466.
70
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because generic drug makers are not permitted to independently update safety information on
drug labeling.77
A recent case contesting the issue of generic drug liability has been decided by
California’s highest court.78 Here, the plaintiff was injured from her prolonged use a generic
form of Fosamax.79 She claimed Teva, the generic maker, had failed to update their warnings in
compliance with the brand Fosamax’s warnings.80 The defense rebutted that the plaintiff’s claim
was preempted by PLIVA. The trial court held, and the appellate court affirmed, that since the
brand-name drug maker made the safety update, the generics are at fault for failing to
immediately update their labels to conform to the newly acquired information.81 This case raised
issues about the scope of PLIVA and whether failure-to-update claims would be preempted by
Federal law.82 The California Supreme Court declined to review the decision, therefore the
pharmaceutical company appealed to the United States Supreme Court.83 The subsequent
petition was denied, leaving the decision about generic drug liability to the FDA.84 The Supreme
Court’s denial of the petition to hear this case may pave the way for similar failure to warn
claims to be brought against generic drug makers in state court.85

77

Silverman, Ed. Lawmakers Ask White House to Review FDA Rule for Generic Label Changes, PHARMALOT
(Sept. 2, 2014), http://blogs.wsj.com/pharmalot/2014/06/26/lawmakers-ask-white-house-to-review-fda-rule-forgeneric-label-changes/.
78
Teva Pharmaceuticals USA, Inc. v. Superior Court, 217 Cal. App. 4th 96 (Cal. App. 4th Dist. 2013).
79
Id.
80
Id.
81
Silverman, Ed. Supreme Court Declines to Review Case About Generic Labeling. (Jan. 21, 2015). PHARMALOT,
http://blogs.wsj.com/pharmalot/2015/01/21/supreme-court-declines-to-review-case-about-generic-labeling/.
82
Id.
83
Id.
84
Id. See also Teva Pharm. USA, Inc. v. Superior Court, 2015 U.S. LEXIS 687, 1 (U.S. Jan. 20, 2015).
85
Kang, Y. Peter, High Court Lets Teva Drug Labeling Suit Go Ahead, LAW 360 (January 20, 2015),
http://www.law360.com/articles/612895/high-court-lets-teva-drug-labeling-suit-go-ahead.
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Similarly, the Alabama Supreme Court recently upheld a suit against brand name
manufacturer for damages caused by the generic form under the concept of “innovator
liability.”86 Here, the court found brand drugs could be liable because the generic manufacturers
relied on the warnings and labels of the brand drug.87 The court relied on the holding in PLIVA,
finding that the federal regulatory scheme made it foreseeable that the brand-name drug owed the
generic version a duty of care.88 The pharmaceutical industry fears that this precedent could
cause a damaging trend throughout the U.S. economy.89
D. Proposed FDA Regulation
Under the current federal regulations, a generic drug manufacturer may only use the
CBE-0 supplement process to update its product labeling to conform to the approved safety label
for the similar brand-name drug.90 A generic drug manufacturer may not independently file a
CBE-0 supplement to the FDA in light of newly acquired safety information or unilaterally
change label its product’s label to add information that is different from the brand-name drug’s
label.91
On November 13, 2013, the FDA proposed to add 21 C.F.R. 317.70(c) (8), which amends
the current regulations and procedures that govern the ability to update and change generic drug
safety labels.92 This proposed rule would allow generic drug manufacturers to independently

86

See Weeks v. Wyeth, Inc., No. 1101397, slip op. (Ala. Aug. 15, 2014).
James W. Huston, Erin M. Bosman, and Julie Y. Park. Weeks II: Innovator Liability Finds a Sweet Home in
Alabama, CLIENT ALERT (August 20, 2014), http://www.mofo.com/~/
media/files/clientalert/2014/08/140820weeksIIInnovatorliability.pdf
88
Id.
89
The Threat of ‘Innovator Liability’, WALL ST. J. (March 13, 2013), available at
http://www.wsj.com/articles/SB10001424127887323628804578346231780434760
90
See 21 U.S.C. 355(j) (1)-(2).
91
Id.
92
Supra note 26.
87
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submit CBE-0 supplements to update labels in light of newly acquired safety information,
regardless of whether this information may differ from the warnings on the brand name drug.93
The generic manufacturer would able to distribute updated safety labels after submitting a
“changes being effected” (CBE-0) supplement to the FDA, as well as safety information
supporting the change.94 The CBE-0 will also notify the maker of the listed drug of the newly
acquired safety information.95
To make updated safety information readily available to the public and to avoid
confusion, the FDA proposed to establish a webpage where the FDA will post new safety
information acquired from the CBE-0 supplements.96
This proposed rule would allow a generic drug to display a label that is temporarily
inconsistent with the labels of the listed drug.97 The FDA would then evaluate whether the
change is justified and make a decision on the generic and listed drug change at the same time,
and as a result, both drugs will have the same FDA approved label.98 After the FDA has
approves the safety label change, there will be a thirty day time frame in which all drug
manufacturers of the “same” drug will have to submit a CBE-0 supplement with conforming
label changes.99
The amended regulations would also permit generic drugs which no longer have a brand
name counterpart to update their own labels. Under current regulations, there is no technique to

93

Id.
Id.
95
Id.
96
Id.
97
Id.
98
Press Release, U.S. Food and Drug Administration, FDA Takes Action To Speed Safety Information Updates on
Generic Drugs (Nov. 8, 2013) http://fda.gov/newsevents/newsroom/pressannouncements/ucm374171.htm
99
Supra note 22.
94

16

accomplish such label change, and therefore, these drugs are being sold on the market with
potentially incorrect or out-of-date safety information.100 The FDA estimates approximately 420
drugs are sold only in the generic form, and the listed drug is no longer manufactured.101 Current
FDA regulations also prohibit a generic drug manufacturer from sending a “Dear Doctor” letter
which would inform physicians of updated and new safety warning information.102
Part III: Reexamining the Current FDA Regulations to Permit Generic Drug
Manufacturers to Update Safety Labels

FDA-approved drug labeling provides patients with essential information needed for the
safe and effective use of a drug, and reflects the FDA’s findings of the safety and effectiveness
under the labeled conditions of use.103 Scholars argue that “[t]he primary purpose of labeling for
prescription drugs is to provide health care practitioners with the essential scientific information
needed to facilitate prescribing decisions, thereby enhancing the safe and effective use of
prescription drug products and reducing the likelihood of medication errors.”104 This safety
information is used by practitioners and patients to make decisions about prescription drugs by
weighing the stated risks against the benefits.105
As of 2010, nearly 90% of pharmaceuticals in the United States are filled with a generic
brand despite the availability of a substitute.106 Despite the changes in the market, and the

100

Carlson, supra note 8.
Zieve, Allison. Guaranteeing Patient Safety, U.S. NEWS (Sept. 22, 2014),
http://www.usnews.com/opinion/articles/2014/03/27/fdas-generic-drug-lableing-proposal-guarantees-patient-safety
102
Boyd, supra note 55.
103
Supra note 23.
104
Id.
105
Id.
106
HHS, ASPE Issue Brief: Expanding the Use of Generic Drugs, (Sept. 22, 2014), available at
http://aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.shtml
101
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evolution of the generic drug industry, the regulations concerning generic labeling have
remained largely unchanged.107
Generic drug makers may not always be able to quickly inform consumers of updated safety
information, because they are not able to act under the same authority as their brand name
counterparts.108 Generic drugs must maintain an identical label to their brand-name substitutes,
and are only required to update safety labels when the brand name has filed a CBE Supplement
with the FDA and the change has been approved.109
A. Public Policy Favors Informing Patients and Physicians of Changes in Drug Safety
Information
The side effects and risks of taking a particular drug may not come to light until after the
drug has been approved by the FDA.110 Therefore, both brand name and generic makers are
required to have written procedures for the review, surveillance and reporting of adverse drug
information, and any “serious and unexpected” drug experiences to the FDA.111 Information
obtained from any source, foreign or domestic, or any type of post-marketing study or
investigation must be reviewed.112 Both brand-name and generic manufacturers must comply
with postmarking reports by submitting an annual report to the FDA including a summary of
information that may affect the drug’s safety, effectiveness, or labeling, as well as a description
of the actions taken in response to the new information and proposed revisions to the safety
labels.113
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The Supreme Court ruling in PLIVA sparked the concern that generic labels are not
sufficient to warn consumers of the risks associated with medications.114 Public policy favors
informing health care practitioners and patients of safety information regarding the prescription
medications. The public will benefit as a result of manufacturers updating drug safety labels in
response to newly acquired safety information.115 Allison Zieve, head of the litigation group at
Public Citizen, commented “[n]o drug is safe in all situations. A drug is safe when used in
accordance with labeling that accurately reflects the known risks. The sooner generic drug
companies are allowed to make safety updates, the better for public health.”116 The public is
harmed when a regulatory delay allows a safety gap and relevant information is not readily
available to the affected parties.117 The ability to update safety information ensures that patients
have the most recent and reliable information about their medications, and can make an informed
choice on whether to take a prescribed drug.
The proposed amendments to current FDA regulation will permit generic drug makers to
update product labeling to “reflect data obtained through post-market surveillance.”118 Although
the proposed amendment does not require generic manufactures to conduct new clinical tests, it
will allow the manufacturers to inexpensively update labels when adverse information is
received and investigated while keeping prices lower than brand-name counterparts.119 Some
argue prices will increase due to the liability generic drug makers would face.120 However,
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proponents believe generic drug makers will not face an increase in litigation because lawsuits
would be less likely to occur when generic drugs are able to update safety information,
preventing injury from occurring altogether.121 The FDA states the proposed regulation will
“provide incentive to generic drug companies to actively participate with the FDA in ensuring
the timeliness, accuracy and completeness of drug safety labeling.”122
“This proposal will help equip health care providers and consumers who depend on
generic drugs with the best possible information to avoid adverse outcomes.”123 The public will
benefit because both brand-name and generic drug makers will have the obligation to give
doctors and patients the information necessary to avoid injuries.124 Through this amendment, the
FDA will not only be able to preserve the principal of “sameness” between brand-name and
generic drugs, but will also allow patients to have better information of a drug’s potential risks
and benefits, regardless of the manufacturer.125
Many opponents of the regulations claim that the time period where labels may differ will
cause confusion and lead to over-warning.126 However, under the current regulations when a
brand-name drug has a safety label update, it can take several months before the generic drug
manufacturers updates their labels with the new warnings.127 Also, brand-name drugs have had
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the ability to update their own safety labels for over thirty years, and there has never been a
problem with over warning of safety information.128
The confusion concerning the temporary differences in brand and generic labels will be
outweighed by the benefit to public health.129 Dr. Janet Woodcock, director of the FDA's Center
for Drug Evaluation and Research stated “It is expected that a valid safety concern regarding a
generic drug product also would generally warrant submission of a supplement for change to the
labeling by the application holder for the corresponding brand drug, as well as other generic drug
application holders.”130 Therefore, it can be assumed when new safety information is acquired,
all manufacturers will apply to change the label, reducing the amount of differing labels even
before the FDA has approved the change. Further, the FDA will maintain a website tracking
CBE-0 supplements so health care providers and patients will have access to the newest changes
and updates. Once the FDA approves a CBE-0 supplement, it will continue to be posted on the
site, and a thirty-day timeframe will be established for drug manufacturers to submit a CBE-0
supplement conforming to the label change.131 This will cut down the amount of time differing
labels will be available on the market.132 Under the FD&C Act the FDA is authorized to “require
and, if necessary [order] labeling changes if FDA becomes aware of new safety information that
FDA believes should be included in the labeling of the drug.”133 Therefore, the FDA can
implement a rule allowing generic drugs to independently update warning labels, ensuring the
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newest warnings are available to consumers regardless of whether they take brand name or
generic medication.
Senator Henry Waxman, co-author of the 1984 Hatch-Waxman Act, argued that allowing
generic drugs to update their labels will ease customers’ concerns about the danger of taking
generic drugs because they will be aware of the latest risks and safety information. Waxman
further argued it will aid in preventing consumers from believing generic drugs are not as safe as
brand name drugs because generics will have more incentive to warn consumers about safety
issues and will be able to get the information out to consumers.134 Generic drug manufactures
have already proven that generic drugs are equally as safe as the brand-name counterpart and the
FDA has agreed.135 Gary Beuhler, Director of the FDA’s office of Generic Drugs argued
“[m]ost people believe that if something costs more, it has to be better quality. In the case of
generic drugs, this is not true. The standards for quality are the same for brand name and generic
products.”136
As generic drugs’ market shares increase, brand name drugs lose incentive to engage in
safety monitoring.137 Dr. Woodcock further argued “[t]he FDA cannot monitor all post-approval
data by itself, drug safety is threatened when the regulatory and common-law incentives
designed to motivate manufacturer diligence weaken with shifting control of market share.”138
Because the generic drug has the majority of the market share, they will probably receive the
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most reports concerning risks and adverse experiences using the drug.139 Generic manufacturers
therefore may be in a better position to update product safety labels because they serve a larger
amount of the population.140 Under the current system, the generic manufacturers cannot update
safety information until the brand-name takes action.141
Allowing generic drug manufacturers to independently update product safety labels in
light of newly acquired safety information will be a great benefit to public health by increasing
patient safety and awareness, while keeping costs and confusion at a minimum.
B. Generic Drugs Will Continue to be an Affordable Alternative to Brand-Name Prescriptions
Generic drugs are more affordable because manufacturers do not need to spend money on
costly clinical trials. Even if generics had more responsibility under the proposed regulation, the
savings would still be apparent.142 The proposed rule would assist in keeping liability costs
down by preventing injuries from occurring in the first place through efficient safety label
updates.143
Currently, generic drugs are shielded from liability because they cannot update their
labels. If a generic drug maker becomes aware of a risk, they cannot change safety labels unless
the brand name does so.
Critics of the proposed regulation fear that allowing generic drug makers to update their
product safety labels will open them up to failure-to-warn lawsuits.144 However, if the injuries
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had never occurred, there would be no law suit.145 Allison Zieve of Public Citizen testified in
front of the House of Representatives Subcommittee on Health:
Because immunizing the companies from liability does not make the
injured patients’ costs go away. The medical expenses and lost
wages from lost work time still exist; they are carried by the patients,
health insurers, and taxpayers, through Medicare or Medicaid.
Because the proposed rule will give generic manufacturers the tools
and incentive to update safety labeling, any costs of the rule should
be offset by cost savings—savings in medical care for the patients
who will not be injured because physicians and patients are armed
with updated labeling about safety risks.146

Critics also fear that generic may over-warn to avoid liability. However, proponents have
noted since the ruling in Wyeth there has not been a surge in CBE-0 supplements to update
brand-name labels, therefore there should not be a worry for over warning by generic drug
makers.147
According to the FDA, "the main reason generic drug companies can market their drugs
at lower prices is that they don't face the same development costs as brand-name companies."148
Generic drugs are approved through an expedited process, and are permitted to skip costly
clinical trials provided that the drug is the “same” and the “bioequivalent” of its brand-name
counterpart.149 The proposed regulation does not place any new requirements for generic drugs
to undergo separate clinical trials and testing, therefore the costs to consumers should remain
low.150 Allison Zieve stated “[g]eneric competition [also] helps keep the cost of drugs down . . .
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it also encourages the research based drug companies to keep finding new and better medicines
that have patent protection.”151
An estimate published by the consulting firm Matrix Global Advisors stated the
proposed rule would lead to approximately a 5% annual increase in spending on generic
drugs.152 The FDA has examined the economic impacts of the proposed regulation and has
determined:
the proposed rule would only impose new burdens on small generic
drug manufacturers who submit CBE-0 supplements for safetyrelated labeling changes. The FDA believes the impact will not be
significant due to the low-cost of submission, and the uncertainty of
the amount of supplements that may be filed.153

C. Allowing Generic Drug Makers to Update Product Safety Labels will Provide a Means for
Generic Drugs which no Longer have a Brand Name Counterpart to Make Safety Updates
The FDA estimates there is approximately 420 drugs that are sold only in the generic
form.154 The Generic Pharmaceuticals Association states that number is even larger, estimating
that about 45% of generic drugs have no brand-name counterpart.155 There is a gap in the current
regulatory system for generic drugs whose brand-name drug counterpart is no longer sold on the
market. Since a brand name drug is only permitted to update safety warnings on product labels,
the generic drugs that no longer have a brand-name counterpart are left without a means of
updating safety label information.156 Currently, there are no clear and efficient methods to
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disseminate information to health care providers as well as the public about newly discovered
safety risks.157
This is concerning because serious drug risks may not be identified until after the generic
drug enters the market, and several generic drugs no longer have a corresponding brand-name
drug on the market.158 Without a corresponding brand-name drug, there are no available
resources to conduct on-going investigations as to the safety of the drug.159 Therefore, drugs that
are only available in generic form are not being continuously monitored and investigated, and
there is no way to update the drug’s label if new safety information were to come to their
attention.
Part IV: Conclusion
The FDA has acknowledged the growth of the generic pharmaceutical industry, and its
impact on the United States’ health industry. Today, generic drugs fill almost 90% of all
pharmaceuticals in the United States, yet consume only 27% of total drug spending, resulting in
huge savings to American consumers every year.160
The Hatch-Waxman Act of 1984 allowed for generic drugs to be approved through an
abbreviated process, provided the generic drug was the “same” in ingredients, dosage, and
administration, and was the “bioequivalent” of the brand-name drug.161 The enactment led to a
greater number of generic drug approvals, and millions of dollars of savings in drug costs to
American consumers.162
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The FDASIA and GDUFA were enacted in 2012 in response to the emerging generic
drug industry. The GDUFA was enacted to increase safety and accessibility of generic drugs,
and provide transparency by inspecting all generic drug facilities.163 The Act was designed to
expedite the approval process of generic drugs, and as a result, cut down the backlog of pending
approvals.164 As generic drugs continue to take an increasing amount of market share, the
government has responded by imposing similar burdens and benefits on generics as brand name
drugs through GDUFA. Allowing generic drugs to file CBE-0 changes and update labels would
conform to this emerging trend.
The proposed regulation to permit generic drug manufacturers to update their safety
labels without FDA approval, and independent of the brand-name drug’s label will result in an
increase of safety information that is beneficial to public health. Patients and physicians will be
up to date with the newest safety information concerning generic drugs, which are used by the
majority of Americans today.
Although this may create temporary differences between generic and brand-name drug
labels, it will increase patient safety overall. Allowing generic drug manufacturers to
independently update safety labels will also encourage them to monitor and research the safety of
marketed drugs. It may also increase the quality of the drugs being manufactured by creating
liability for generic products.
Updating the FDA’s current regulations will also create an opportunity for generic drugs
that no longer have a brand-name counterpart to keep patients up-to-date on the newest safety
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information, and provide a consistent method for updating safety labels for all drugs and
prescriptions in the United States.
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